Neurocrine Biosciences, Inc. provided revenue guidance for the fourth quarter and full year ended December 31, 2017. For the quarter, the company expects net product sales of INGREZZA® (valbenazine) to be approximately $64 million. Total company revenues for the fourth quarter are expected to be approximately $94 million inclusive of a $30 million milestone payment received from AbbVie for the FDA's acceptance of the elagolix endometriosis NDA in the fourth quarter. For the full year, the company expects net product sales of INGREZZA are expected to be approximately $116 million and total company revenues of approximately $161 million inclusive of $45 million revenue recognized from its collaboration agreements with AbbVie and Mitsubishi Tanabe Pharma Corporation.